Innovations in Neuromodulation

Industry trends from key opinion leaders, acquirers and 13 early-stage companies

International Neuromodulation Society 11th World Congress

BERLIN--()--In "Innovations in Neuromodulation," the International Neuromodulation Society (INS) brings together over 200 entrepreneurs, thought leaders, innovators and investors June 9th to focus on developments in this rapidly changing field. The day includes:

  • Executives presenting from 13 innovative, early-stage neuromodulation companies:
Aleva Neurotherapeutics, SA       Mainstay Medical, Inc.       Nexstim Oy
Algostim, LLC NeuroNexus Stimwave Technologies, Inc.
Biotectix, LLC Neuros Medical, Inc. W.I.S.E., S.r.l
EndoStim Neurosigma, Inc.
Functional Neuromodulation, Ltd. Neurotargeting, LLC
  • Regulatory pathways and winning strategies – INS Past President Dr. Elliot Krames and President Dr. Simon Thomson
  • What big companies look for when they buy small companies – Boston Scientific, Johnson & Johnson, Medtronic, and Sorin Group
  • How to raise money for a startup – Nevro Corp. Chief Business Officer Rami Elghandour
  • Insight into the innovation process, intellectual property, industry trends, market penetration and forecasts – serial entrepreneur Dr. Danny Sachs
  • Intelligence on medical device investment strategies and challenges; enabling neuroscience and emerging therapies, companies, and platforms; global industry alliances and acquisitions – Dr. Eric Grigsby, chief executive officer, Neurovations; medical director, Napa Pain Clinic
  • Trends in CE Mark and FDA regulatory approvals in Europe and the U.S. – regulatory affairs strategist Winifred Wu
  • Evidence for payers – Rod Taylor, Ph.D., professor in Health Services Research
  • Keynote speech – former Advanced Neuromodulation Systems, Inc. Chief Executive Officer Chris Chavez
  • Networking with medical device industry leaders and emerging therapy innovators

The talks precede scientific sessions at the INS 11th World Congress. “Technology Transforming Chronic Illness Management” at the Estrel Hotel in Berlin, Germany, June 8 - 13, 2013, with comprehensive tracks on all neuromodulation therapies:

About the International Neuromodulation Society (INS)

The INS is a nonprofit group of clinicians, scientists and engineers dedicated to scientific development and knowledge of neuromodulation, a rapidly growing family of therapies developed to help relieve pain or restore function by delivering electromagnetic stimulation or chemical agents to specific sites in the body. Founded in 1989 and based in San Francisco, Calif., the INS has 15 current and four forming chapters worldwide, and educates and promotes the field through meetings, its journal Neuromodulation: Technology at the Neural Interface, and chapter websites. For more information, please visit


International Neuromodulation Society
Nancy Garcia, +1 415-683-3237

Release Summary

Neuromodulation therapy investment and trends discussed by world leaders.


International Neuromodulation Society
Nancy Garcia, +1 415-683-3237